BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Mar 12, 2025 • 17min
Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine
Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.
Mar 12, 2025 • 10min
Tour of Scotland: Edinburgh based Cumulus Oncology has built a hub and spoke model of creating multiple spin-out companies - it already has three disclosed assets
Founder & CEO Clare Wareing describes the company's design, with an eye towards being capital efficient and investing over and again for the long-term. She describes the lead investments: a PARG inhibitor, GPR68 small molecules, and a GTPase inhibitor.
Mar 12, 2025 • 8min
Tour of Scotland: Outrun Therapeutics is aiming to create a new category of therapeutics by stabilizing proteins via drugging E3 ligases
CEO Carolyn Porter describes the beginning of the company, which spun out of University of Dundee's MRC Protein Phosphorylation and Ubiquitylation Unit (PPU). The first goal is to go after hard to treat solid tumors.
Mar 11, 2025 • 9min
Tour of Scotland: Tay Therapeutics is a product of University of Dundee's Drug Discovery Unit, and is working on small molecules - including a topical pan-BET that is in phase 2
Founder and CEO Andrew Woodland describes how they made the decision to focus on inflammation for the pan-BET, which is partnered with VYNE Therapeutics. VYNE has also completed a phase 1a with Tay's oral selective BET inhibitor. Plus, how Tay is also working on a small molecule gene therapy program.
Mar 11, 2025 • 24min
Tour of Scotland: University of Dundee has established a world-class Centre for Protein Degradation, one of the hottest emerging modalities in biotech
Founder and Director Alessio Ciulli explains the science behind protein degradation. He then describes the facilities that have been built and the work that takes place at the centre, including founding companies like Amphista Therapeutics. Plus, his take on the field more broadly and targets that researchers are going after.
Mar 11, 2025 • 5min
Tour of Scotland: The Head of Business Development at University of Dundee's Drug Discovery Unit talks about how the university helps biopharma companies translate science into medicines
Charlotte Green describes the work that the unit does in tropical diseases, CNS, women's health, and oncology. She also highlights their pharma partnerships and licenses, and cases where independent biotech companies have spun out of the work.
Mar 11, 2025 • 10min
Tour of Scotland: Sir Michael Ferguson introduces the work in life sciences that has built up at The University of Dundee and the specialized centers that have come from it
He discusses speciality work relating to molecular cell biology / signal transduction, and translational science. Plus, the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU), the Drug Discovery Unit, the soon-to-open Innovation Hub, and more.
Mar 10, 2025 • 10min
A study published in JMIR today showed that Limbic's GenAI-powered chatbot elevated the standard of care for mental health patients in the UK’s National Health Service (NHS)
Limbic CEO Ross Harper describes how patients who interacted with Limbic Care attended 42% more therapy sessions and achieved a 25% higher recovery rate compared to standard treatment.
Mar 6, 2025 • 36min
Analyst Thursdays: William Blair Senior Analyst Andy Hsieh talks about his new obesity sector report and the companies he initiated
He discusses what to look for in safety and efficacy, new targets, and his thoughts on the potential role of oral therapies. Plus, comments on Structure Therapeutics, Corbus, Skye Bioscience, Zealand, Viking, Altimmune, Terns, and BioAge Labs.
Feb 28, 2025 • 12min
On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science
Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.
